A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors
Phase 1 Terminated
11 enrolled
PORTSIDE
Phase 2 Terminated
38 enrolled
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
Phase 1 Terminated
29 enrolled
Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®
Phase 3 Terminated
52 enrolled
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
Phase 1 Terminated
10 enrolled
Tamarack
Phase 2 Terminated
192 enrolled 20 charts
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Phase 1/2 Terminated
46 enrolled 22 charts
A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
45 enrolled 44 charts
A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers
Phase 1 Terminated
22 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
RELATIVITY-098
Phase 3 Terminated
1,093 enrolled 15 charts
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Phase 1 Terminated
78 enrolled
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
Phase NA Terminated
2 enrolled
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2 Terminated
31 enrolled
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Phase 1 Terminated
17 enrolled
A Study of ASP1012 in Adults With Solid Tumors
Phase 1 Terminated
15 enrolled
PAVO
Phase 2 Terminated
22 enrolled 17 charts
MAVIS
Phase 3 Terminated
504 enrolled 23 charts
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Phase 1 Terminated
65 enrolled 52 charts
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
Phase 1/2 Terminated
31 enrolled 12 charts
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
Phase 1 Terminated
67 enrolled
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
31 enrolled
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
Phase 1 Terminated
105 enrolled
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Phase 1 Terminated
10 enrolled
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Phase 2 Terminated
23 enrolled 15 charts
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Phase 1 Terminated
75 enrolled
COMBI-i
Phase 3 Terminated
568 enrolled 28 charts
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Phase 1 Terminated
9 enrolled
CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma
Phase 2/3 Terminated
20 enrolled 18 charts
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
Phase 1 Terminated
227 enrolled
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Phase 1 Terminated
88 enrolled
Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors
Phase 1 Terminated
44 enrolled
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Phase 1 Terminated
20 enrolled
CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma
Phase 2 Terminated
44 enrolled 19 charts
ARTISTRY-6
Phase 2 Terminated
173 enrolled
A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma
Phase 2 Terminated
11 enrolled 8 charts
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Phase 1 Terminated
60 enrolled
RAPTOR
Phase 1 Terminated
27 enrolled
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
Phase 1 Terminated
241 enrolled
A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma
Phase 1 Terminated
22 enrolled
Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma
Phase 1 Terminated
7 enrolled
Study of INCB086550 in Select Solid Tumors
Phase 2 Terminated
16 enrolled 17 charts
A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp
Phase 3 Terminated
563 enrolled 15 charts
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Phase 2 Terminated
205 enrolled 54 charts
STARLING
Phase 1 Terminated
31 enrolled
ATL001 in Patients With Metastatic or Recurrent Melanoma
Phase 1/2 Terminated
13 enrolled 14 charts
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Phase 1 Terminated
8 enrolled
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Phase 1 Terminated
133 enrolled
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1/2 Terminated
15 enrolled